BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BC Innovations | Mar 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
BC Innovations | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 4 (OX40; TNFRSF4; CD134)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest agonizing OX40 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an agonist anti-OX40 antibody delayed disease onset and decreased the...
BC Week In Review | Nov 23, 2015
Clinical News

GSK3174998: Phase I started

GlaxoSmithKline began an open-label, U.S. Phase I trial to evaluate 0.003-10 mg/kg IV GSK3174998 every 3 weeks for up to 48 weeks alone or with IV Keytruda pembrolizumab in about 264 patients. The first part...
BC Week In Review | Nov 23, 2015
Company News

Merck, GlaxoSmithKline deal

The companies partnered to conduct a U.S. Phase I trial to evaluate Merck’s Keytruda pembrolizumab with GlaxoSmithKline’s GSK3174998 to treat patients with locally advanced, recurrent or metastatic solid tumors that have progressed after standard treatment....
BC Extra | Nov 4, 2015
Company News

GSK aims for 20 filings by 2020

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said at its R&D day Tuesday that it hopes to submit up to 20 pipeline candidates for approval by 2020, with an additional 20 filings to follow in 2021-25. GSK highlighted...
Items per page:
1 - 7 of 7